Asset
DARATUMUMAB
Johnson & Johnson Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $4.2B |
| Q1 2026 | $4.0B |
| Q4 2025 | $3.9B |
| Q3 2025 | $3.7B |
| Q2 2025 | $3.5B |
| Q1 2025 | $3.2B |
| Q4 2024 | $3.1B |
| Q3 2024 | $3.0B |
| Q2 2024 | $2.9B |
| Q1 2024 | $2.7B |
| Q4 2023 | $2.5B |
| Q3 2023 | $2.5B |
| Q2 2023 | $2.4B |
| Q1 2023 | $2.3B |
| Q4 2022 | $2.1B |
| Q3 2022 | $2.1B |
| Q2 2022 | $2.0B |
| Q1 2022 | $1.9B |
| Q4 2021 | $1.6B |
| Q3 2021 | $1.6B |
| Q2 2021 | $1.4B |
| Q1 2021 | $1.4B |
| Q4 2020 | $1.3B |
| Q3 2020 | $1.1B |
| Q2 2020 | $901.0M |
| Q1 2020 | $937.0M |
| Q4 2019 | $830.0M |
| Q3 2019 | $765.0M |
| Q2 2019 | $774.0M |
| Q1 2019 | $629.0M |
| Q4 2018 | $584.0M |
| Q3 2018 | $498.0M |
| Q2 2018 | $511.0M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (37)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02076009 | phase3 | completed | 2014-07-23 | 2016-03-07 | Janssen Research & Development, LLC | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma |
| NCT03652064 | phase3 | completed | 2018-11-06 | 2024-05-07 | Janssen Research & Development, LLC | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy |
| NCT04181827 | phase3 | active_not_recruiting | 2020-06-12 | 2024-05-01 | Janssen Research & Development, LLC | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma |
| NCT05455320 | phase3 | active_not_recruiting | 2022-10-13 | 2027-07-30 | Janssen Research & Development, LLC | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment |
| NCT03768960 | phase4 | completed | 2019-06-10 | 2022-07-16 | Johnson & Johnson Private Limited | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 761036 | BLA | Janssen Biotech, Inc. |
Marketed products (2)
- DARZALEX
- DARZALEX